Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Betere ziektevrije overleving met adjuvant alectinib bij NSCLC
mei 2024 | Longoncologie